Chong Kun Dang Pharmaceutical Corporation

Chong Kun Dang Corporation

Incheon University Industry Academic Cooperation Foundation

Samjin Pharmaceutical Co., Ltd.

Bamichem Co., Ltd.

Incheon National University Research & Business Foundation

Aptabio Therapeutics Inc.

Min Hyo Ki

Hee Jong Shin

Young Nam Lee

So Hyun Park

Ho Young Hwang

Sang Myoung Noh

Sung Won An

Jin Young Ko

Jong Min Kim

Jung Woo Kim

Hyun Tae Kim

Ji Yeon Kim

Sung Hwan Moon

Sung Pyo Hong

Soon Kil Ahn

Soo Jin Lee

Jong Lae Lim

Jae Woong Lee

Ji Hee Lee

Eui Hwan Cho

Hee-Jeong Cho

Ho Seok Kwon

Ha Na Yu

Jeong Ho Joo

Won Kyu Yang

Hong Woo Lee

Sang Joon Lee

Jae Soo Shin

Sang Phil Yoon

Keun Kuk Lee

Sung Bum Jung

Ji Hye Hwang

Hyoung Min Cho

Ki Seong Ko

Hye Jung Baik

Ah-Reum Chae

Su Kyoung Lee

Bok Young Kim

Young Hun Lee

Sung Hye Kim

Sung Hyun Kang

Yong Bin Park

Ji Hyeh Hwang

Ji Hyun Um

Yu Mi Ji

Kug Hwa Lee

Eunsun Song

Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent.

Composition for gene delivery comprising chitosan and liquid crystal formation material

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof

Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same

Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.

Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same

Disclosed is a pharmaceutical composition for gene delivery, comprising: (i) a gene; (ii) a water-soluble chitosan; (iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof; (iv) a protamine or a pharmaceutically acceptable salt thereof; and (v) a neutral or anionic phospholipid. The composition can introduce a gene into cells safely and effectively. Composed of non-toxic and injectable components, the composition is safe for the body and can be advantageously commercialized. Notably, it can deliver a gene at high efficiency in vivo as well as in vitro, and is stable in the blood.

Composition for gene delivery

Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.

Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof

Acetamenophen composition with reduced liver toxicity

Growing community of inventors

Gyeonggi-do, South Korea

Min Hyo Ki